At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
Tamoxifendrug
Likely dose
Tamoxifen 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Hormone Therapy With Tamoxifen in Patients With Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
In Brief
A Phase 2 clinical trial evaluating Tamoxifen for Neuroendocrine Tumors and 2 related conditions. Completed, enrolled 23 participants across 2 sites in 2 countries.
Detailed Summary
This is a single-arm, unicentric, single-stage clinical study of tamoxifen for patients with well differentiated neuroendocrine tumors and radiological progression with positive (\> 1 percent) HR (estrogen and / or progesterone) expression by IHC. It will evaluate if Tamoxifen exerts antitumor action in patients with well differentiated NET and positive for the expression of HR, estrogen and / or progesterone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor
CountriesBrazil, United States
CollaboratorsH. Lee Moffitt Cancer Center and Research Institute
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMar 2019
Enrollment StartMar 2019
Primary CompletionMay 2023
TodayJul 2026
First PostedMar 12, 2019
Enrollment StartMar 13, 2019
Primary CompletionMay 13, 2023
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 7.3 years ago
Interventions
Tamoxifendrug
The treatment to be used will be tamoxifen 20mg orally once daily.